Ellington Management Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

Ellington Management Group’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-57,800	Closed	-$304K	–	1108
2017 Q4	$304K	Buy	+57,800	New	+$354K	0.05%	365
2016 Q4	–	Sell	-19,300	Closed	-$181K	–	913
2016 Q3	$181K	Buy	+19,300	New	+$160K	0.05%	562
2015 Q3	–	Sell	-12,700	Closed	-$192K	–	983
2015 Q2	$192K	Buy	+12,700	New	+$183K	0.05%	599
2015 Q1	–	Sell	-18,700	Closed	-$333K	–	885
2014 Q4	$333K	Buy	+18,700	New	+$233K	0.11%	307

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ellington Management Group's PETX Position: Q1 2018 in Review

Ellington Management Group sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2018, closing a stake of 57,800 shares — an estimated $304K sold.

Ellington Management Group first reported a position in PETX in Q4 2014 and held it in 4 quarters. The position peaked at $333K in Q4 2014. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

Ellington Management Group reported no remaining Aratana Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Ellington Management Group sold 57,800 Aratana Therapeutics, Inc. shares in Q1 2018, an estimated $304K.
Ellington Management Group first reported a position in Aratana Therapeutics, Inc. in Q4 2014 and held it in 4 quarters.
Ellington Management Group's Aratana Therapeutics, Inc. position peaked at $333K in Q4 2014.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on Ellington Management Group's 13F filing for Q1 2018, filed 15 May 2018.